|
gptkbp:instanceOf
|
antineoplastic agent
anthracycline antibiotic
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvedBy
|
1979 (US FDA)
|
|
gptkbp:ATCCode
|
L01DB02
|
|
gptkbp:CASNumber
|
20830-81-3
|
|
gptkbp:color
|
red-orange
|
|
gptkbp:contraindication
|
hypersensitivity to anthracyclines
severe cardiac impairment
|
|
gptkbp:derivedFrom
|
gptkb:Streptomyces_peucetius
|
|
gptkbp:discoveredBy
|
gptkb:Federico_Arcamone
|
|
gptkbp:discoveredIn
|
1963
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
18.5 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C27H29NO10
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
daunorubicin
|
|
gptkbp:KEGGID
|
D00275
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA synthesis
inhibits topoisomerase II
intercalates DNA
|
|
gptkbp:MeSH_ID
|
D003638
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
527.52 g/mol
|
|
gptkbp:otherName
|
gptkb:daunomycin
gptkb:rubidomycin
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
30323
CHEMBL534
|
|
gptkbp:riskFactor
|
gptkb:secondary_leukemia
extravasation injury
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
alopecia
cardiotoxicity
mucositis
myelosuppression
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
1U1QTN40SY
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
leukemia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:ABCC1
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|